Innovent Biologics (SEHK:1801): Examining Valuation Following Significant Share Price Gains

Simply Wall St.

Yesterday

Innovent Biologics (SEHK:1801) shares have shown modest movement over the past week, following recent shifts in sentiment across the broader biotech market. Investors are considering the company’s ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578465905"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578465905\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578465905?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-10-26 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578465905","market":"nz","top_or_hot":-1,"title":"Innovent Biologics (SEHK:1801): Examining Valuation Following Significant Share Price Gains","media":"Simply Wall St.","content":"<div>\n<p>Innovent Biologics (SEHK:1801) shares have shown modest movement over the past week, following recent shifts in sentiment across the broader biotech market. Investors are considering the company’s ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-examining-valuation-following-si\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics (SEHK:1801): Examining Valuation Following Significant Share Price Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics (SEHK:1801): Examining Valuation Following Significant Share Price Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-26 21:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-examining-valuation-following-si><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innovent Biologics (SEHK:1801) shares have shown modest movement over the past week, following recent shifts in sentiment across the broader biotech market. Investors are considering the company’s ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-examining-valuation-following-si\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-examining-valuation-following-si","article_id":"2578465905","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-examining-valuation-following-si","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2578465905","pubTimestamp":1761484906,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Innovent Biologics (SEHK:1801) shares have shown modest movement over the past week, following recent shifts in sentiment across the broader biotech market. Investors are considering the company’s overall performance dynamics and how they compare to sector peers.\nSee our latest analysis for Innovent Biologics.\nInnovent Biologics’ share price has soared 140.99% year-to-date, signaling strong momentum after a sustained rally. The latest uptick is likely fueled by renewed optimism over the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","BK1161":"生物科技","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","BK1583":"高瓴概念","01801":"信达生物","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK1589":"北水核心资产"},"translate_title":"信达生物（SEHK：1801）：股价大幅上涨后审视估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"01801":0.9},"content_text":"Innovent Biologics (SEHK:1801) shares have shown modest movement over the past week, following recent shifts in sentiment across the broader biotech market. Investors are considering the company’s overall performance dynamics and how they compare to sector peers. See our latest analysis for Innovent Biologics. Innovent Biologics’ share price has soared 140.99% year-to-date, signaling strong momentum after a sustained rally. The latest uptick is likely fueled by renewed optimism over the company’s growing pipeline and sector tailwinds. Over the past 12 months, long-term investors have enjoyed a total shareholder return of 93.33%. That multi-year track record of 216.27% over three years continues to set the company apart from many biotech peers. If you’re looking to spot more high-potential health innovators, take the next step and explore See the full list for free. With such impressive gains already on the table, the key question is whether Innovent Biologics' current valuation leaves room for further upside, or if the market has already taken much of its future growth potential into account. AdvertisementPrice-to-Earnings of 118.7x: Is it justified? Innovent Biologics is currently priced at a lofty 118.7 times earnings, far exceeding what is typical for Asian biotech firms, with its last close at HK$85.55. This valuation puts it at a clear premium not only to the market, but also to its direct industry peers and potential fair value benchmarks. The price-to-earnings (P/E) ratio helps investors gauge how much they are paying for each dollar of the company’s current profits. In high-growth sectors like biotech, a high P/E can be justified by rapid expansion or expectations of substantial future profits. However, with Innovent’s P/E standing at 118.7, investors are pricing in significant optimism about future earnings potential. For context, the Asian biotechs average a P/E of 44.7, while peer companies average 37.5, and the estimated fair P/E for Innovent is also 37.5. This suggests the market is already anticipating a much rosier outlook than what is reflected in industry standards or regression-based fair value models. Explore the SWS fair ratio for Innovent Biologics Result: Price-to-Earnings of 118.7x (OVERVALUED) However, slower than expected revenue growth or shifts in biotech sector sentiment could quickly challenge the company’s premium valuation and future expectations. Find out about the key risks to this Innovent Biologics narrative. Another View: What Does the SWS DCF Model Say? While the market is assigning a steep valuation to Innovent Biologics using earnings multiples, our DCF model offers a different perspective. According to this approach, the stock is trading 19.3% below its estimated fair value. Could this suggest hidden upside or simply reflect optimism included in future cash flows? Look into how the SWS DCF model arrives at its fair value. 1801 Discounted Cash Flow as at Oct 2025Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Innovent Biologics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Innovent Biologics Narrative If you have a different perspective or want to investigate further, you can easily analyze the numbers and craft your own view in just a few minutes with Do it your way. A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Innovent Biologics. Looking for more investment ideas? There are countless other exciting opportunities waiting for you. Don’t let them slip by. Uncover your next big winner using these specially curated screens:  Catch the momentum with stocks that may be undervalued and poised for growth by starting your search at these 876 undervalued stocks based on cash flows. Target steady portfolio income and find companies delivering attractive yields through these 17 dividend stocks with yields > 3%, tailored for income-focused investors. Stay ahead of the trend and spot healthcare innovators leveraging artificial intelligence with these 33 healthcare AI stocks.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}